[Long-term efficacy and predictors of response to infliximab in Korean patients with Crohn's disease].
暂无分享,去创建一个
[1] J. Shim,et al. [Clinical outcome of treatment with infliximab in Crohn's disease: a single-center experience]. , 2013, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.
[2] A. Ford,et al. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. , 2012, Journal of Crohn's & colitis.
[3] T. Einarson,et al. Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis , 2011, Pharmacoepidemiology and drug safety.
[4] W. Reinisch,et al. Review article: infliximab for Crohn’s disease treatment – shifting therapeutic strategies after 10 years of clinical experience , 2011, Alimentary pharmacology & therapeutics.
[5] P. Rutgeerts,et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.
[6] M. Picco. Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease , 2010 .
[7] P. Rutgeerts,et al. Mucosal healing predicts long‐term outcome of maintenance therapy with infliximab in Crohn's disease , 2009, Inflammatory bowel diseases.
[8] Eun Hee Kim,et al. [Efficacy of infliximab in the treatment of korean patients with crohns disease]. , 2009, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.
[9] K. Van Steen,et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort , 2008, Gut.
[10] M. Vatn,et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[11] J. S. Kim,et al. [Efficacy and safety of treatment with infliximab in Crohn's disease-the experience of single center in Korea]. , 2005, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.
[12] M. Bala,et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. , 2005, Gastroenterology.
[13] L. Beaugerie,et al. Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery , 2005, Gut.
[14] P. Rutgeerts,et al. Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.
[15] P. Rutgeerts,et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. , 2004, Gastroenterology.
[16] F. Carbonnel,et al. Long-Term Evolution of Disease Behavior of Crohn's Disease , 2002, Inflammatory bowel diseases.
[17] S. Hanauer,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[18] A. Zinsmeister,et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. , 2001, Gastroenterology.
[19] M. Kamm,et al. Infliximab for the treatment of fistulas in patients with Crohn'S disease. , 1999, Gastroenterology.
[20] S. Targan,et al. A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .
[21] S. Targan,et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. , 1997, The New England journal of medicine.